Is Pfizer’s New Business Big Enough To Carry The Old One?

Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.

A Fifth Of The Company Is Doing The Growing

In the second quarter of 2026, launched and acquired products brought in $3.2 billion of a $15 billion quarter. That line holds Padcev, the bladder cancer medicine from the Seagen deal, and NURTEC for migraine. The obesity programs that came with Metsera are not in that line yet, and are still investigational, with the first potential approvals beginning in 2028. Management points to that line when it explains how Pfizer grows again.

Total revenue rose 1% operationally in the same quarter. The launched and acquired line itself grew 18% operationally in the quarter. The growth is real. It is just coming off a small base.

And The Rest Is Where The Patents Run Out

The other four-fifths faces significant headwinds due to approaching patent expirations and moderating demand. It carries the COVID business, where management says low COVID-19 incidence could keep limiting Paxlovid use. It also carries the in-line medicines the company says are approaching loss of exclusivity, the patent cliff ahead of Pfizer.

Management’s stated plan is to keep investing behind the launched and acquired products so they offset those losses over the next several years. That is the handoff. It has to happen while the older medicines are still most of the revenue.

Then Pfizer Wrote Down $4.3 Billion

The pipeline is meant to widen that fifth. In the second quarter of 2026, two programs went the other way. Pfizer recorded $4.3 billion of noncash intangible asset impairments. A Phase III lung cancer trial missed its main survival endpoint, and the company removed its revenue projection for Oxbryta.

Because this was a noncash accounting impairment, it did not impact the company’s immediate cash balances or operational liquidity. What left was part of the value Pfizer had put on those two programs; management still forecasts significant risk-adjusted revenue for the lung cancer program in other indications, subject to technical and regulatory success. Relative to Pfizer’s market capitalization of approximately $165 billion, this impairment represents an absorbed setback rather than a structural balance-sheet threat. It is also a reminder that the handoff runs on things that have not happened yet.

So You Are Being Asked To Wait Through 2028

This is not a crisis, but the second quarter showed the handoff can slip. Pfizer wrote off $4.3 billion when a lung cancer trial missed and the Oxbryta forecast came out. Management’s own aim, a risk-adjusted high single-digit revenue growth rate, does not begin until the end of 2028 and runs through 2033. You are paying near the 52-week high for the handoff to go right through then.

Follow one line in each quarterly report: the launched and acquired revenue, and whether its share of the total climbs. Option implied volatility—trading at the 55th percentile of its own past year range—indicates that derivatives markets are not pricing in outsized operational disruption.

Do You Buy Pfizer For The Handoff?

Perhaps, but only if you can hold through years when the new medicines are still the smaller part of the company. That means judging a pipeline and a patent calendar at the same time, on a single company. Most people would rather not make those calls alone. If that is you, look at the Trefis High Quality Portfolio. That portfolio has a track record of outpacing the three major indices.